Pfizer News - May 2026
Pfizer cuts prostate cancer progression risk 52%, targeting specific gene mutations
Pfizer reported Phase 3 TALAPRO-3 study results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluated a combination of...
Pfizer's first quarter 2026 revenue of $14.5B beats estimates, driven by 22% growth in new and acquired products.
Pfizer reported first-quarter 2026 revenues of $14.5 billion, representing 2% year-over-year operational growth, and an adjusted diluted EPS of $0.75. The...
Pfizer Inc Q1 2026 Earnings Preview: What Analysts Expect on May 05, 2026
For the first quarter of 2026, analysts anticipate Pfizer will report a consensus revenue of $13.82 billion and adjusted EPS of $0.74, while the stock...